Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore
Background: Trastuzumab (Herceptin) can be administered intravenously (IV Herceptin) and subcutaneously, with similar efficacy and safety, but with differences in dosage and costs. Previous studies have evaluated the costs of both treatment approaches in the outpatient settings, but no study has com...
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
SAGE Publishing
2024-11-01
|
| Σειρά: | Therapeutic Advances in Medical Oncology |
| Διαθέσιμο Online: | https://doi.org/10.1177/17588359241293381 |